NCT04474925
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Radiation therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with prior whole brain radiation therapy or stereotactic radiosurgery to the lesion being resected at time of study accrual; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04474925